TISSGGRYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARDĪnd a light chain variable domain of: TABLE-US-00045 (SEQ ID NO:Ħ3) DVVMTQTPLSLPVSLGMASISCRSSQSLVYSNGNTYLHWYLQKPGOSPKV ID NO: 62) EVQLVESGGDLVKPGGSLKLSCAARSRFTFSNYGMSWVRQTPDKRLEWVA The binding protein of claim 73, wherein the binding proteinĬomprises (a) a heavy chain variable domain of: TABLE-US-00044 (SEQ NO: 157) RSSQSLVYSNGNTYLH (ii) CDR-L2: (SEQ ID NO: 48) KVSNRFS Īnd (iii) CDR-元: (SEQ ID NO: 49) SQSTHVPLT.ħ7. TISSGGRYTYYPDSVKG and (iii) CDR-H3: (SEQ ID NO: 46) DYLYAMDY,Īnd a light chain CDR set of: TABLE-US-00043 (i) CDR-L1: (SEQ ID ID NO: 92) RFTFSNYGMS (ii) CDR-H2: (SEQ ID NO: 93) The binding protein of claim 73, wherein the binding proteinĬomprises a heavy chain CDR set of: TABLE-US-00042 (i) CDR-H1: (SEQ IYYTDNLQTGIPSRFSGSGSGTDYTLTISSLQPEDVATYYCYQYNSGP TFGAGTKLELQ.ħ6. Wherein X.sub.2 is N, T, R, W or P and X.sub.3 is G, E, L or K orĭIQMSQSPPVLSASVGDRVILSCKASQNIHKNLDWYQQKHGEAPKLLI QSPKVLMYKVSNRFSGVSDRFSGSGSGTDFTLKISRVEAEDLGVYFCS Wherein X.sub.1 is R or S or TABLE-US-00039 (SEQ ID NO: 59)ĮVQLVESGGGINQPGRSLKLSCAASGFTVSDYYMAWVRQAPKKGLEWVĪSISYEGSSTYYGDSVKGRFTISRDNAKSILYLQMNSLRSEDTATYYCĪnd/or (b) the light chain comprises a variable domain comprisingĪn amino acid sequence of TABLE-US-00040 (SEQ ID NO: 52)ĭVVMTQTPLSLPVSLGDQASISCRSSQSLVYSX2X3NTYLHWYLQKPG The binding protein of claim 73, wherein: (a) the heavy chainĬomprises a variable domain comprising an amino acid sequence ofĮVQLVESGGDLVKPGGSLKLSCAASRFTFSNFGMSWVRQTPDKRLEWVĪTISSGGRYTYYPDX1VKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYĬARDYLYAMDYWGQGTSVTVSS, or (SEQ ID NO: 51)ĮVQLVESGGDLVKPGGSLKLSCAASRFTFSNYGMSWVRQTPDKRLEWV Set is selected from any set of heavy chain CDRs listed in TablesĢ-4, and the light chain CDR set is the corresponding light chainħ5. The binding protein of claim 73, wherein the heavy chain CDR
SQSTHVPLT (SEQ ID NO: 49) or YQYNSGPT (SEQ ID NO: 58).ħ4.
(SEQ ID NO: 48) or YTDNLQT (SEQ ID NO: 57) and (iii) CDR-元: NO: 47), wherein X.sub.3 is N, T, W or P, and wherein X.sub.4 is G,Į, L or K, or KASQNIHKNLD (SEQ ID NO: 56) (ii) CDR-L2: KVSNRFS (SEQ ID NO: 46) or PLRYYGYNYRFAY (SEQ ID NO: 55), and the lightĬhain CDRs are: (i) CDR-L1: RSSQSLVYSX.sub.3X.sub.4NTYLH (SEQ ID Or SISYEGSSTYYGDSVKG (SEQ ID NO: 54) and (iii) CDR-H3: DYLYAMDY TISSGGRYTYYPDX.sub.2VKG (SEQ ID NO: 10), wherein X.sub.2 is S or H, X.sub.1 is F or Y or GFTVSDYYMA (SEQ ID NO: 53) (ii) CDR-H2: A binding protein capable of binding LRP-8, comprising a heavyĬhain comprising a set of three heavy chain CDRs (CDR-H1, CDR-H2,Īnd CDR-H3), and a light chain comprising a set of three lightĬhain CDRs (CDR-L1, CDR-L2, and CDR-元), wherein the heavy chainĬDRs are: (i) CDR-H1: RFTFSNX.sub.1GMS (SEQ ID NO: 9), wherein
MA) Hanzatian Denise Karaoglu (Natick, MA) Argiriadi Maria A. (Northborough, MA) Deng Kangwen (Shrewsbury, Localize to the brain and/or localize to the spinal cord. To LRP-8 and optionally cross the blood brain barrier (BBB), The disclosure provides binding proteins that specifically bind Argiriadi, Lorenzo Benatuil, Kangwen Deng, Denise Karaoglu Hanzatian. The applicant listed for this patent is AbbVie Inc. This patent application is currently assigned to AbbVie Inc. patent application number 14/967260 was filed with the patent office on for lrp-8 binding proteins.